HDAC6-selective inhibitor A452 can enhance sensitivity of acquired bortezomib (BTZ)-resistant multiple myeloma cells to bortezomib by inhibiting the activation of ERK and NF-κB in [64]. Here, HDAC6 is linked to plasma cell myeloma.